Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6518
    +0.0018 (+0.28%)
     

  • OIL

    82.96
    +0.15 (+0.18%)
     

  • GOLD

    2,330.30
    -8.10 (-0.35%)
     

  • Bitcoin AUD

    98,678.03
    -3,587.78 (-3.51%)
     

  • CMC Crypto 200

    1,391.35
    +8.78 (+0.63%)
     

  • AUD/EUR

    0.6076
    +0.0006 (+0.09%)
     

  • AUD/NZD

    1.0953
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,218.50
    +17.23 (+0.10%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Why Atea Pharmaceuticals Stock Got Crushed This Week

George Budwell, The Motley Fool
·2-min read
Why Atea Pharmaceuticals Stock Got Crushed This Week

Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

Continue reading